07:00 , Apr 7, 2003 |  BioCentury  |  Tools & Techniques

Splitting the essential difference for asthma

A good target for inflammatory disease occurs early in the cascade but is selective enough not to interfere with functions that maintain homeostasis. Last week, Abgenix Inc. partnered with Sosei Co. Ltd. to obtain access...
07:00 , Aug 20, 2001 |  BioCentury  |  Strategy

Nowhere to hide

Shareholders hammered the value of Bayer AG last week after management owned up to the consequences of the removal of its Baycol/Lipobay cholesterol drug from the market. But if the sell-off was stunning, its plunging...
08:00 , Jan 29, 2001 |  BioCentury  |  Strategy

Bayer's pipeline

Bayer's pipeline...